Global Finance News
19 Nov 2025, 17:15
Dexcom Smart Basal cleared by FDA as first CGM-integrated basal insulin dosing optimizer
Dexcom announced FDA clearance for Dexcom Smart Basal, making it the first and only CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using glargine U-100 long-acting insulin. The system uses Dexcom G7 15-Day sensor data plus logged insulin doses to generate personalized daily dose recommendations, aiming to simplify and accelerate basal insulin initiation. The tool continuously analyzes all CGM readings rather than relying on a single fasting measurement and automatically adjusts recommendations when low-glucose events occur. Smart Basal will be incorporated into the Dexcom G7 15-Day app shortly after its U.S. launch, with international expansion planned.
Dexcom announced FDA clearance for Dexcom Smart Basal, making it the first and only CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using glargine U-100 long-acting insulin. The system uses Dexcom G7 15-Day sensor data plus logged insulin doses to generate personalized daily dose recommendations, aiming to simplify and accelerate basal insulin initiation. The tool continuously analyzes all CGM readings rather than relying on a single fasting measurement and automatically adjusts recommendations when low-glucose events occur. Smart Basal will be incorporated into the Dexcom G7 15-Day app shortly after its U.S. launch, with international expansion planned.
